Company intelligence / Profile preview

Ultradian Diagnostics

Rensselaer, New York, USA

Ownership: Private
Employees: ~4
Development stage: Other

Overview

Completed 5-day clinical study of Biologue CGM with MARD of 11.3%, demonstrating proof of concept for single-point calibration and insulin pump integration.

Therapeutic areas: Endocrinology
Modalities: Continuous Glucose Monitoring (CGM)
Industry: Physiological Monitoring

Beyond the preview

Go deeper on Ultradian Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ultradian Diagnostics.

Explore the full profile